Education, Counseling Associated with Improved Clinical Outcomes in Type 2 Diabetes

Web Exclusives - Conference Highlights ADA
Wayne Kuznar

San Diego, CA—Patients with type 2 diabetes who use education and counseling services offered by their managed care plan have better glycemic control and lower diabetes health-related costs. However, few managed care patients with type 2 diabetes use these services, investigators from Premier Research Services, Charlotte, NC, found in a study presented at the 2011 Scientific Sessions of the American Diabetes Association.

The researchers examined medical and pharmacy data from the Premier-i3 Continuum of Care database, which links a large outpatient research database with a large hospital database. Included in this analysis were 26,790 adult patients with type 2 diabetes. Of these, 2490 (9.3%) received 1 or more education and counseling interventions; 90.7% received no education and counseling.

Diabetes education (73.2%) and nutrition/diet counseling (21.0%) were the most common forms of education and counseling intervention.

After 12 months of follow-up, the mean hemoglobin (Hb)A1c level was 6.7% among those in the education/counseling group, which was significantly lower than the 7.5% in the control group (no education/counseling service used).

Patients who used education/counseling had a 4-fold greater likelihood of achieving glycemic control than the control group. An HbA1c level <7.0% was achieved in 71.9% of patients who received education/counseling compared with 51.3% in the control group.

Education/counseling had no significant effect on the incidence of hypoglycemia; slightly more than 1.0% in each group had a hypoglycemic event.

A matched cohort (based on demographic and baseline factors) of 1890 patients was also evaluated. In this analysis, 12-month HbA1c values were again lower in the group that received education/counseling, and the odds for achieving glycemic control were still 4 times greater in this group versus the control group. In the education/counseling group, 71.0% of patients achieved HbA1c levels <7.0% compared with 48.6% in the group that did not receive education/counseling. As in the unmatched cohort, the percentage of hypoglycemic events was similar in the 2 groups.

In the unmatched cohort, the total healthcare costs were similar between the 2 groups at 12 months: $22,531 in the education/counseling group and $22,121 in the control group. Patients in the education/counseling group, however, had a 43% decrease in diabetes-related costs compared with the control group ($5313 vs $11,448).

In the matched cohort, total healthcare costs were higher in the education/counseling group versus the control group ($24,747 vs $18,378), but diabetes-related charges were again lower in the education/counseling group versus the control group ($6795 vs $9130).

Patients who received education/counseling were more likely to be women and to have lower levels of comorbidity compared with individuals who did not receive such support.

Related Items
Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights published on February 27, 2019
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME